The Expora Platform™
The Expora Platform™ unlocks bacterial extracellular vesicle (EV) manufacturing at scale with Generally Regarded As Safe (GRAS) probiotic producer cells at orders of magnitude lower costs than conventional EV therapies, creating a foundation for future therapeutics.
Patent-Protected Platform
The Expora Platform™ technology is over a decade in development and a product of over $10M of government funded research. Our comprehensive characterization and rigorous release testing ensure patients receive the highest standard of safety and efficacy.
Scalable Manufacturing
The Expora Platform™ solves complex CMC challenges through optimized fermentation, scalable purification, and stringent quality controls. Our cost-effective processes produce oral formulations with extended shelf life and capable of rapid scaling from development to commercial volumes.
Precision Medicine by Design
Bacterial EVs are uniquely designed to treat gastrointestinal inflammation. Our technology harnesses EVs from clinically efficacious bacteria, native to human gut, and engineered to produce bioactive agents that modulate inflammation without systemic toxicities.
